Celecoxib: A new augmentation strategy for depressive mood episodes. A systematic review and meta-analysis of randomized placebo-controlled trials

Human Psychopharmacology

Volumn 29, Issue 3, 2014, Pages 216-223

  Faridhosseini, Farhad ^a   Sadeghi, Ramin ^b   Farid, Layla ^a   Pourgholami, Meysam ^a  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

celecoxib; cyclooxygenase 2 inhibitors; depression; depressive disorders; meta analysis

Indexed keywords

ANTIDEPRESSANT AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; PYRAZOLE DERIVATIVE; SULFONAMIDE;

BIPOLAR DISORDER; DEPRESSIVE DISORDER; DEPRESSIVE DISORDER, MAJOR; DRUG COMBINATION; HUMAN; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; CYCLOOXYGENASE 2 INHIBITORS; DEPRESSIVE DISORDER; DEPRESSIVE DISORDER, MAJOR; DRUG THERAPY, COMBINATION; HUMANS; PYRAZOLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SULFONAMIDES;

EID: 84898828778     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.2401     Document Type: Review

References (52)

1. Abbasi SH, Hosseini F, Modabbernia A, Ashrafi M, Akhondzadeh S,. 2012. Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study. J Affect Disord 141 (2-3): 308-314.
2. Akhondzadeh S, Tabatabaee M, Amini H, Ahmadi Abhari SA, Abbasi SH, Behnam B,. 2007. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophr Res 90: 179-185.
3. Akhondzadeh S, Jafari S, Raisi F, et al,. 2009. Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress Anxiety 26 (7): 607-611.
4. Calabrese JR, Skwerer AG, Barna B, et al,. 1986. Depression, immunocompetence, and prostaglandins of the E series. Psychiatry Res 17: 41-47.
5. Chen CY, Tzeng NS, Chen YC,. 2010. Maintenance therapy of celecoxib for major depression with mimicking neuropsychological dysfunction. Gen Hosp Psychiatry 32 (6): 647.e7-9.
6. Collantes-Estevez E, Fernandez-Perez C,. 2003. Improved control of osteoarthritis pain and self-reported health status in nonresponders to celecoxib switched to rofecoxib: results of PAVIA, an open-label post-marketing survey in Spain. Curr Med Res Opin 19: 402-410.
7. Costello EJ, Erkanli A, Angold A,. 2006. Is there an epidemic of child or adolescent depression? J Child Psychol Psychiatry 47: 1263-1271.
8. Danese A, Moffitt TE, Pariante CM, et al,. 2008. Elevated inflammation levels in depressed adults with a history of childhood maltreatment. Arch Gen Psychiatry 65: 409-415.
9. Dersimonian R, Laird N,. 1986. Meta-analysis in clinical trials. Control Clin Trials 7: 177-188.
10. Dinan TG,. 2009. Inflammatory markers in depression. Curr Opin Psychiatry 22: 32-36.
11. Dowlati Y, Herrmann N, Swardfager W, et al,. 2010. A meta-analysis of cytokines in major depression. Biol Psychiatry 67: 446-457.
12. Dunn AJ, Swiergiel AH, de Beaurepaire R,. 2005. Cytokines as mediators of depression: what can we learn from animal studies? Neurosci Biobehav Rev 29: 891-909.
13. Duval S, Tweedie R,. 2000. Trim and fill: a simple funnel plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56: 455-463.
14. Egger M, Davey Smith G, Schneider M, Minder C,. 1997. Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634.
15. Guo JY, Li CY, Ruan YP, et al,. 2009. Chronic treatment with celecoxib reverses chronic unpredictable stress-induced depressive-like behavior via reducing cyclooxygenase-2 expression in rat brain. Eur J Pharmacol 612 (1-3): 54-60.
16. Hantouche EG, Akiskal HS, Lancrenon S, Chatenêt-Duchêne L,. 2005. Mood stabilizer augmentation in apparently "unipolar" MDD: predictors of response in the naturalistic French national EPIDEP study. J Affect Disord 84: 243-249.
17. Hashemian F, Majd M, Hosseini SM, Sharifi A, Panahi MVS, Bigdeli O,. 2011. A randomized, double-blind, placebo-controlled trial of celecoxib augmentation of sertraline in the treatment of a drug-naive women with major depression. Klin Psikofarmakol B 21: S183-S184.
18. Iyengar RL, Gandhi S, Aneja A, et al,. 2013. NSAIDs are associated with lower depression scores in patients with osteoarthritis. Am J Med pii: S0002-9343(13)00358-6.
19. Jon DI, Kim DH, Seo HJ, et al,. 2013. Augmentation of aripiprazole for depressed patients with an inadequate response to antidepressant treatment: a 6-week prospective, open-label, multicenter study. Clin Neuropharmacol 36 (5): 157-161.
20. Jones KA, Thomsen C,. 2013. The role of the innate immune system in psychiatric disorders. Mol Cell Neurosci 53: 52-62.
21. Khoraminya N, Tehrani-Doost M, Jazayeri S, Hosseini A, Djazayery A,. 2013. Therapeutic effects of vitamin D as adjunctive therapy to fluoxetine in patients with major depressive disorder. Aust N Z J Psychiatry 47 (3): 271-275.
22. Konstam MA, Weir MR,. 2002. Current perspective on the cardiovascular effects of coxibs. Cleve Clin J Med 69 (Suppl 1): SI47-SI52.
23. Lee HJ, Ertley RN, Rapoport SI, Bazinet RP, Rao JS,. 2008. Chronic administration of lamotrigin down regulates COX-2 mRNA and protein in rat frontal cortex. Neurochem Res 33: 861-866.
24. Li G, Mbuagbaw L, Samaan Z, et al,. 2013. Efficacy of vitamin D supplementation in depression in adults: a systematic review protocol. Syst Rev 2: 64.
25. Linnoila M, Whorton R, Rubinow DR, Cowdry RW, Ninan PT, Waters RN,. 1983. CSF prostaglandin levels in depressed and schizophrenic patients. Arch Gen Psychiatry 40: 405-406.
26. Martinez JM, Garakani A, Yehuda R, Gorman JM,. 2012. Proinflammatory and "resiliency" proteins in the CSF of patients with major depression. Depress Anxiety 29 (1): 32-38.
27. McNally L, Bhagwagar Z, Hannestad J,. 2008. Inflammation, glutamate, and glia in depression: a literature review. CNS Spectr 13: 501-510.
28. McNamara RK, Lotrich FE,. 2012. Elevated immune-inflammatory signaling in mood disorders: a new therapeutic target? Expert Rev Neurother 12 (9): 1143-1161.
29. Mendlewicz J,. 2008. Towards achieving remission in the treatment of depression. Dialogues Clin Neurosci 10: 371-375.
30. Miller AH, Maletic V, Raison CL,. 2009. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 65: 732-741.
31. Moodley I,. 2008. Review of the cardiovascular safety of COXIBs compared to NSAIDS. Cardiovasc J Afr 19 (2): 102-107.
32. Mtabaji JP, Manku MS, Horrobin DF,. 1977. Actions of the tricyclic antidepressant clomipramine on responses to pressor agents. Interactions with prostaglandin E2. Prostaglandins 14: 125-132.
33. Muller N,. 2010. COX-2 inhibitors as antidepressants and antipsychotics: clinical evidence. Curr Opin Investig Drugs 11: 31-42.
34. Müller N, Riedel M, Scheppach C, et al,. 2002. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry 159 (6): 1029-1034.
35. Müller N, Schwarz MJ, Dehning S, et al,. 2006. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry 11 (7): 680-684.
36. Müller N, Krause D, Dehning S, et al,. 2010. Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophr Res 121 (1-3): 118-124.
37. Muller N, Myint AM, Schwarz MJ,. 2011. Inflammatory biomarkers and depression. Neurotox Res 19: 308-318.
38. Nelson JC, Papakostas GI,. 2009. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo controlled randomized trials. Am J Psychiatry 166 (9): 980-991.
39. Nery FG, Monkul ES, Hatch JP, et al,. 2008. Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study. Hum Psychopharmacol 23 (2): 87-94.
40. Nishino S, Ueno R, Ohishi K, Sakai T, Hayaishi O,. 1989. Salivary prostaglandin concentrations: possible state indicators for major depression. Am J Psychiatry 146: 365-368.
41. Ohishi K, Ueno R, Nishino S, Sakai T, Hayaishi O,. 1988. Increased level of salivary prostaglandins in patients with major depression. Biol Psychiatry 23: 326-334.
42. Ong HT, Ong LM, Tan TE, Chean KY,. 2013. Cardiovascular effects of common analgesics. Med J Malaysia 68 (2): 189-194.
43. Papakostas GI, Shelton RC, Smith J, Fava M,. 2007. Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. J Clin Psychiatry 68 (6): 826-831.
44. Qureshi NA, Al-Bedah AM,. 2013. Mood disorders and complementary and alternative medicine: a literature review. Neuropsychiatr Dis Treat 9: 639-658.
45. Schatzberg AF,. 2008. Achieving remission and favorable outcomes in patients with depression/anxiety and substance use disorders. CNS Spectr 13: 10-12.
46. Sigalas PD, Garg H, Watson S, McAllister-Williams RH, Nicol Ferrier IN,. 2012. Metyrapone in treatment-resistant depression. Ther Adv Psychopharmacol 2 (4): 139-149.
47. Song C, Lin A, Bonaccorso S, et al,. 1998. The inflammatory response system and the availability of plasma tryptophan in patients with primary sleep disorders and major depression. J Affect Disord 49: 211-219.
48. Trivedi MH,. 2009. Treating depression to full remission. J Clin Psychiatry 70: e01.
49. Vidrih B, Karlovic̈ D, Pasic̈ MB, Uremovic̈ M, Mufic̈ AK, Matosic̈ A,. 2012. A review of the psychoneuroimmunologic concepts on the etiology of depressive disorders. Acta Clin Croat 51 (3): 403-409.
50. WHO. 2008. Projections of mortality and burden of disease, 2004-2030. Retrieved 4 December 2010, from: http://www.who.int/ healthinfo/global-burden- disease/projections/en/index.html
51. Wright BM, Eiland EH 3rd, Lorenz R,. 2013. Augmentation with atypical antipsychotics for depression: a review of evidence-based support from the medical literature. Pharmacotherapy 33 (3): 344-359.
52. Yaron I, Shirazi I, Judovich R, Levartovsky D, Caspi D, Yaron M,. 1999. Fluoxetine and amitriptyline inhibit nitric oxide, prostaglandin E2, and hyaluronic acid production in human synovial cells and synovial tissue cultures. Arthritis Rheum 42: 2561-2568.